
The Manufacturer
ANSELL HEALTHCARE EUROPE N.V.
RIVERSIDE BUSINESS PARK, BLOCK J
BOULEVARD INTERNATIONAL 55
B-1070 BRUSSELS
BELGIUM
WWW.ANSELL.COM

declares under his sole responsibility, that the PPE described hereafter:



is in conformity with the provisions of Regulation (EU) 2016/425 and with the standards EN 388:2016 +A1:2018, EN407:2020, EN ISO 21420:2020, EN ISO 374-1:2016, EN ISO 374-5:2016 and is identical to the PPE which is subject to the EU-Type examination (Module B, Annex V of the Regulation), under certificate number 032/2021/1032, issued by the Notified Body:

CENTEXBEL (0493) TECHNOLOGIEPARK 70 B-9052 ZWIJNAARDE BELGIUM

and is subject to the procedure set out in Annex VIII (Module D) of the Regulation under the supervision of the Notified Body:

CENTEXBEL (0493)
TECHNOLOGIEPARK 70
B-9052 ZWIJNAARDE
BELGIUM

Guido Van Duren

Director - Regulatory affairs

Ansell

Place: Brussels Date: 2021/10/12

The Manufacturer
ANSELL HEALTHCARE EUROPE N.V.
RIVERSIDE BUSINESS PARK, BLOCK J
BOULEVARD INTERNATIONAL 55
B-1070 BRUSSELS
BELGIUM
WWW.ANSELL.COM

declares under his sole responsibility, that the PPE described hereafter:

AlphaTec® 39-124

Products manufactured as of: [2019/10/29] and till: [2021/10/11]

PPE to be used against category III risks









4111B

X1XXXX

is in conformity with the provisions of Regulation (EU) 2016/425 and with the standards EN ISO 374-1:2016 Type B, EN ISO 374-5:2016, EN 388:2016, EN 420:2003 + A1:2009, EN 407:2004 and is identical to the PPE which is subject to the EU-Type examination (Module B, Annex V of the Regulation), under certificate number 032/2019/0046, issued by the Notified Body:

CENTEXBEL (0493) TECHNOLOGIEPARK 70 B-9052 ZWIJNAARDE BELGIUM

and is subject to the procedure set out in Annex VIII (Module D) of the Regulation under the supervision of the Notified Body:

CENTEXBEL (0493)
TECHNOLOGIEPARK 70
B-9052 ZWIJNAARDE
BELGIUM

Guido Van Duren

Director - Regulatory affairs

Ansell

Place: Brussels Date: 2019/10/29

The Manufacturer
ANSELL HEALTHCARE EUROPE N.V.
RIVERSIDE BUSINESS PARK, BLOCK J
BOULEVARD INTERNATIONAL 55
B-1070 BRUSSELS
BELGIUM
WWW.ANSELL.COM

declares under his sole responsibility, that the PPE described hereafter:

AlphaTec® 39-124

Products manufactured as of: [2019/01/14] and till: [2019/10/28]

PPE to be used against category III risks









4111B

X1XXXX

is in conformity with the provisions of Regulation (EU) 2016/425 and with the standards EN ISO 374-1:2016 Type B, EN ISO 374-5:2016, EN 388:2016, EN 420:2003 + A1:2009, EN 407:2004 and is identical to the PPE which is subject to the EU-Type examination (Module B, Annex V of the Regulation), under certificate number 032/2019/0046, issued by the Notified Body:

CENTEXBEL (0493) TECHNOLOGIEPARK 70 B-9052 ZWIJNAARDE BELGIUM

and is subject to the procedure set out in Annex VIII (Module D) of the Regulation under the supervision of the Notified Body:

BSI (0086)
KITEMARK COURT DAVY AVENUE KNOWLHILL
MILTON KEYNES MK5 8PP UNITED KINGDOM

Guido Van Duren

Director - Regulatory affairs

Ansell

Place: Brussels Date: 2019/01/14

The Manufacturer
ANSELL HEALTHCARE EUROPE N.V.
RIVERSIDE BUSINESS PARK, BLOCK J
BOULEVARD INTERNATIONAL 55
B-1070 BRUSSELS
BELGIUM
WWW.ANSELL.COM

declares under his sole responsibility, that the PPE described hereafter:



Products manufactured till: [2019/01/13]

PPE to be used against category III risks









4111

X1XXXX

is in conformity with the provisions of Regulation (EU) 2016/425 and with the standards EN 374:2003, , EN 420:2003 + A1:2009, EN 388:2003, EN 407:2004 and is identical to the PPE which is subject to the EC Type examination; under certificate number 03205294 issued by the Notified Body:

CENTEXBEL (0493) TECHNOLOGIEPARK 70 B-9052 ZWIJNAARDE BELGIUM

and is subject to the procedure set out in Annex VII (Module C2) of the Regulation under the supervision of the Notified Body:

CENTEXBEL (0493) TECHNOLOGIEPARK 70 B-9052 ZWIJNAARDE BELGIUM

Guido Van Duren

Director - Regulatory affairs

Ansell

Place: Brussels Date: 2005/07/08